Immune to Cancer: The CRI Blog
-
Nivolumab Approved for Patients with Chemotherapy-Resistant, Metastatic, MSI-H Colorectal Cancer
Nivolumab becomes second checkpoint immunotherapy approved for colorectal cancer
-
Recapping Our 5th Annual Cancer Immunotherapy Month
The 5th Annual Cancer Immunotherapy Month generated more than 6,000,000 impressions and raised over $500,000.
-
More Than $875,000 Raised at the 2017 Answer to Cancer Cycling Event and 5K Family Fun Run and Walk
With more than 450 bikers, runners, walkers, and volunteers, the 2017 Answer to Cancer was the best…
-
Rational Combinations 360° Seeks Improved Immunotherapy Approaches for Patients
Top immunotherapy experts from both academia and industry will convene for the 2nd annual Rational Combinations 360°…
-
Ask a Scientist About Cancer Immunotherapy Clinical Trials
Dr. Michael Postow responds to patient questions about clinical trials, including finding one, what the different stages…
-
CRI’s CEO, Scientific Advisors Headline Cancer Immunotherapy Forum
The future of immunotherapy is in finding the right combinations
-
ASCO17 Recap: 7 Takeaways from the World’s Premier Clinical Cancer Conference
ASCO17’s presentations reveal that the field of immunotherapy is advancing along many fronts
-
ASCO17: Days 4 and 5 Immunotherapy Highlights
Days 4 and 5 at ASCO17 showed off the overall scope of immunotherapy’s efforts to provide clinical…
-
ASCO17: Day 3 Immunotherapy Highlights
Day 3 at the 2017 annual meeting of the American Society of Clinical Oncology touched on immunotherapy…
Join CRI in Shaping the Future of Immunotherapy
Support the pioneering work of CRI in advancing immunotherapy.